Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118904 | 1.00 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL30118960 | 0.88 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL22426339 | 0.88 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL30118936 | 0.84 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL9525840 | 0.84 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL22406342 | 0.78 | KMT2A (0.51) | RAB9ANPC1KDM4EKMT2AALDH1A1 | |
| SCHEMBL30118917 | 0.78 | KMT2A (0.51) | RAB9ANPC1KDM4EKMT2AALDH1A1 | |
| SCHEMBL7617859 | 0.77 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL7289353 | 0.77 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL30048914 | 0.77 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| EP-3938364-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2022-01-19 | — | — | EP | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | SNCA, PARK7, HTT | RAB9A 1250/4885NPC1 1943/4885SMN1; SMN2 7/4885 |
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | RAB9A 1452/4885NPC1 277/4885SMN1; SMN2 10/4885 |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | SNCA, HTT, PARK7 | RAB9A 1570/4885NPC1 564/4885SMN1; SMN2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.